Overview of allergic mechanisms. Ebastine has more than an antihistamine effect

Drugs

Volumn 52, Issue SUPPL. 1, 1996, Pages 15-19

  Campbell, Alison ^a   Michel, François Bernard ^a   Bremard Oury, Clotilde ^b   Crampette, Louis ^c   Bousquet, Jean ^a  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b SANOFI   (France)

^c Hopital Saint Charles   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CAREBASTINE; CYTOKINE; DRUG METABOLITE; EBASTINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; ICOSANOID; INTERLEUKIN 8; LEUKOTRIENE C4; LEUKOTRIENE D4; PROSTAGLANDIN D2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALLERGIC RHINITIS; ALLERGY; CELL SECRETION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; MALE; NOSE MUCUS; NOSE POLYP; NOSE PROVOCATION TEST; REVIEW;

EID: 0029775852     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199600521-00005     Document Type: Review

References (16)

1. 1-receptor antagonists assessed by nasal challenge. J Allergy Clin Immunol 1988; 82: 881-7
2. Stoop AE, van der Heijden HA, Biewenga J, et al. Eosinophils in nasal polyps and nasal mucosa: an immunohistochemical study. J Allergy Clin Immunol 1993; 91: 616-22
3. Linder A, Karlsson-Parra A, Hirvela C, et al. Immunocompetent cells in human nasal polyps and normal mucosa. Rhinology 1993; 31: 125-9
4. Ohno I, Lea RG, Flanders KC, et al. Eosinophils in chronically inflamed human upper airway tissues express transforming growth factor beta 1 gene (TGF beta 1). J Clin Invest 1992; 89: 1662-8
5. Hamilos DL, Leung DY, Wood R, et al. Chronic hyperplastic sinusitis: association of tissue eosinophilia with mRNA expression of granulocyte-macrophage colony-stimulating factor and interleukin-3. J Allergy Clin Immunol 1993; 92: 39-48
6. Tos M, Sasaki Y, Ohnishi M, et al. Fireside conference 2. Pathogenesis of nasal polyps. Rhinology 1992; 14 Suppl.: 181-5
7. Naclerio RM, Meier HL, Kagey-Sobotka A, et al. In vivo model for the evaluation of topical antiallergic medications. Arch Otolaryngol 1984; 110: 25-7
8. Sim TC, Grant JA, Hilsmeier KA, et al. Proinflammatory cytokines in nasal secretions of allergic subjects after antigen challenge. Am J Respir Crit Care Med 1994; 149: 339-44
9. Campbell AM, Chanez P, Marty-Ane C, et al. Modulation of eicosanoid and histamine release from human dispersed lung cells by terfenadine. Allergy 1993; 48: 125-9
10. Holgate S, Burns G, Robinson C, et al. Anaphylactic and calcium-dependent generation of prostaglandin D2 (PGD2), thromboxane B2 and other cyclo-oxygenase products of arachidonic acid by dispersed lung cells and relationship to histamine release. J Immunol 1984; 133: 2138-44
11. 1-blockers. Int Arch Allergy Immunol 1993; 101: 308-10
12. Lebel B, Bousquet J, Morel A, et al. Correlation between symptoms and the threshold for release of mediators in nasal secretions during nasal challenge with grass-pollen grains. J Allergy Clin Immunol 1988; 82: 869-77
13. Anderson M, Nolte H, Buamgarten C, et al. Suppressive effect of loratadine on allergen-induced histamine release in the nose. Allergy 1991; 46: 540-6
14. Naclerio RM, Kagey-Sobotka A, Lichtenstein LM, et al. Terfenadine, an H1 antihistamine inhibits histamine release in vivo in the human. Am Rev Respir Dis 1990; 142: 167-71
15. Togias AG, Proud D, Kagey-Sobotka A, et al. In vivo and in vitro effects of antihistamines on mast cell mediator release: a potentially important property in the treatment of allergic disease. Ann Allergy 1989; 63: 465-9
16. Shin MH, Baroody F, Proud D, et al. The effect of azelastine on the early allergic response. Clin Exp Allergy 1992; 22: 189-95